Immune checkpoint inhibitors combined with or without radio(chemo)therapy for locally advanced or recurrent/metastatic esophageal squamous cell carcinoma

Objective This study was designed to investigate the efficacy and prognostic factors for immune checkpoint inhibitors (ICIs) combined with or without radio(chemo)therapy and to evaluate their toxicity in patients with locally advanced or recurrent/metastatic esophageal squamous cell carcinoma (LA/RM...

Full description

Saved in:
Bibliographic Details
Published in:Discover. Oncology 2023-09, Vol.14 (1), p.165-165, Article 165
Main Authors: Zhao, Xiao-Han, Gao, Hong-Mei, Wen, Jing-Yuan, Wang, He-Song, Wu, Luan-Ying, Song, Chun-Yang, Deng, Wen-Zhao, Zhu, Shu-Chai, Shen, Wen-Bin
Format: Article
Language:English
Subjects:
Cancer Research
Cancer therapies
Chemotherapy
Dysphagia
Esophageal cancer
Esophageal squamous cell carcinoma
Immunotherapy
Inhibitor drugs
Internal Medicine
Lymphatic system
Medical prognosis
Medicine
Medicine & Public Health
Metastasis
Molecular Medicine
Oncology
Prognosis
Radiation therapy
Radiotherapy
Squamous cell carcinoma
Surgery
Surgical Oncology
Treatment-related adverse events
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective This study was designed to investigate the efficacy and prognostic factors for immune checkpoint inhibitors (ICIs) combined with or without radio(chemo)therapy and to evaluate their toxicity in patients with locally advanced or recurrent/metastatic esophageal squamous cell carcinoma (LA/RM ESCC). Methods In this study, 198 patients with locally advanced or recurrent/metastatic (LA/RM) ESCC who received ICIs combined with or without radiotherapy/chemotherapy in the Department of Radiotherapy of the Fourth Hospital of Hebei Medical University were retrospectively analyzed. Univariate and multivariate analyses were performed to determine the prognostic factors for overall survival (OS) and progression free survival (PFS). The factors affecting treatment response and the occurrences of treatment-related adverse events (trAEs) were analyzed. Results The median OS and PFS were 30.4 months (95% confidence interval [CI] 15.1–45.7 months) and 15.3 months (95% CI 12.8–17.8 months), respectively. Univariate and multivariate analysis showed that the number of ICI cycles, the intervention of radiotherapy and dysphagia were independent factors affecting OS (Hazard ratio [HR] = 0.39, 2.043 and 0.365, respectively; P = 0.018, 0.001 and 0.032, respectively). The intervention of radiotherapy was an independent factor for PFS (hazard ratio [HR] = 18.149, P = 0.013). The median OS and PFS for patients who had complete response and partial response (Objective response, ORR) were 50.8 months (95% CI 25.8–75.7 months) and 20.5 months (95% CI 14.1–27.0), respectively, which were significantly higher than those in the non-ORR group (OS non-ORR :17.5 months, 95% CI 14.0–21.0; χ 2  = 13.881, P  
ISSN:2730-6011
2730-6011
DOI:10.1007/s12672-023-00783-3